INBICON A/S: Financial statements 2023
CVR: 27036635
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
INBICON A/S (CVR 27036635) has filed annual accounts for 2023. In 2023, the company reported a net result of DKK 280,000 compared with DKK -319,000 the year before. Equity in the 2023 report amounted to DKK 31,962,000. The solvency ratio was 99.7%.
- Profit/Loss
- DKK 280,000
- Equity
- DKK 31,962,000
- Total Assets
- DKK 32,072,000
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | - | 280 t. | 32 mio. | - |
| 2022 | 0 | -498 t. | -319 t. | 31.7 mio. | - |
| 2021 | 0 | -518 t. | -1.6 mio. | 32 mio. | - |
| 2020 | 0 | 25.7 mio. | 21.3 mio. | 33.6 mio. | - |
| 2019 | - | 4.6 mio. | 3.5 mio. | 12.3 mio. | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
INBICON A/S has published its annual report for 2022. Revenue came to DKK 0, and the net result was DKK -319,000.
About INBICON A/S
INBICON A/S is a Danish company of the type Aktieselskab based in Fredericia, founded in 2003. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named ELSAM BIOSYSTEMS A/S and KR 354 A/S. The management consists of Thomas Søndergaard Lyse. The board consists of Ole Thomsen (chair), Jens Grymer and Thomas Søndergaard Lyse. The company is owned by Ørsted New Bio Solutions Holding A/S. The company has 0 employees (2011). In 2025, the company reported a net result of DKK -3,447,000 compared with DKK 7,237,000 the year before. Equity in the 2025 report amounted to DKK 35,752,000.